Publications by authors named "Florante R Ricarte"

Teriparatide (PTH (1-34)), PTHrP (1-36), and abaloparatide (ABL) have been used for the treatment of osteoporosis, but their efficacy long term is significantly limited. The 3 peptides exert time- and dose-dependent differential responses in osteoblasts, leading us to hypothesize they may also differentially modulate the osteoblast transcriptome. Treatment of mouse calvarial osteoblasts with 1 nM of the peptides for 4 hours results in RNA sequencing data with PTH (1-34) regulating 367 genes, including 194 unique genes; PTHrP (1-36) regulating 117 genes, including 15 unique genes; and ABL regulating 179 genes, including 20 unique genes.

View Article and Find Full Text PDF

Teriparatide (PTH(1-34)) and its analogs, PTHrP(1-36) and abaloparatide (ABL) have been used for the treatment of osteoporosis, but their efficacy over long-term use is significantly limited. The 3 peptides exert time- and dose-dependent differential responses in osteoblasts, leading us to hypothesize that they may also differentially modulate the osteoblast transcriptome. We show that treatment of mouse calvarial osteoblasts with 1 nM of the 3 peptides for 4 h results in RNA-Seq data with PTH(1-34) regulating 367 genes, including 194 unique genes; PTHrP(1-36) regulating 117 genes, including 15 unique genes; and ABL regulating 179 genes, including 20 unique genes.

View Article and Find Full Text PDF
Article Synopsis
  • Osteoporosis results from the loss of sex hormones and aging, with abaloparatide (ABL) being a significant treatment option similar to teriparatide.
  • PTH(1-34) generates a stronger cAMP response and activates protein kinase A (PKA) more effectively than PTHrP(1-36) and ABL in osteoblasts.
  • All three peptides have distinct effects on gene regulation linked to PKA signaling, highlighting the intricate molecular pathways involved in osteoblast function and the potential for improved osteoporosis treatments.
View Article and Find Full Text PDF